Hiv was the largest of GSK plc’s 10 reported lines in fiscal 2025, at $15.37B — 24% of $65.33B.
| Products and services [axis] | FY 2015 | FY 2016 | FY 2020 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Shingles, Meningitis, Rsv, Influenza & Established Vaccines | $18.28B | — | |||
| Vaccines | $18.28B | — | |||
| Respiratory | $14.43B | $14.14B | |||
| Established Pharmaceuticals | — | — | |||
| Hiv | $14.18B | $15.37B | |||
| Respiratory, Immunology Inflammation | $6.60B | $7.62B | |||
| Other General Medicines | $6.43B | $5.94B | |||
| Wellness | — | — | |||
| Established Vaccines | $6.68B | $6.24B | |||
| Shingles | $6.73B | $7.12B | |||
| Oral Care | — | — | |||
| Immuno-Inflammation, Respiratory & Other | — | — | |||
| Oncology | $2.82B | $3.95B | |||
| Meningitis | $2.87B | $3.17B | |||
| Nutrition | — | — | |||
| Rsv (Arexvy) | $1.18B | $1.19B | |||
| Skin Health | — | — | |||
| Influenza | $816.00M | $606.00M | |||
| Immuno Inflammation | — | — | |||
| Pandemic | $24.00M | — | |||
| Total | $99.30B | $65.33B |
In fiscal 2025, which ended December 31, 2025, the 10 revenue lines GSK plc reported in this breakdown added up to $65.33B. The revenue lines reported changed from fiscal 2024, so the total is not directly comparable with the $99.30B reported that year. Hiv was the largest revenue line, at $15.37B or 23.5% of the total, followed by Respiratory ($14.14B, 21.6%) and Respiratory, Immunology Inflammation ($7.62B, 11.7%). Together, the two largest revenue lines made up 45.2% of this total.
Compared with fiscal 2024, Oncology grew the fastest, rising 40.2% to $3.95B. Other General Medicines fell the most, down 7.7% to $5.94B. Because revenue lines were added or dropped between the two years, part of this reflects how GSK plc regrouped its reporting.
The table also keeps 10 revenue lines that GSK plc no longer reports, so earlier years can still be read on their original basis; use "Show 10 discontinued" beneath the table to see them. This breakdown covers 5 fiscal years between 2015 and 2025, as reported in GSK plc's annual filings.
Us was the largest of GSK plc’s 3 reported lines in fiscal 2025, at $33.72B — 69% of $48.78B.
| Geography | FY 2015 | FY 2016 | FY 2019 | FY 2020 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Rest Of World | — | — | — | ||||
| Rest Of World. | — | — | — | ||||
| Us | $31.64B | $32.77B | $33.72B | ||||
| International | $15.89B | $16.65B | — | ||||
| Europe | — | $11.92B | $13.70B | ||||
| Uk Current Year Charge | $1.39B | $1.42B | $1.37B | ||||
| Uk | — | — | — | ||||
| Total | $48.91B | $62.75B | $48.78B |
In fiscal 2025, which ended December 31, 2025, the 3 regions GSK plc reported in this breakdown added up to $48.78B. That is less than the $65.33B in its breakdown by revenue line, so these regions do not account for all of its revenue that year. Us was the largest region, at $33.72B or 69.1% of the total, followed by Europe ($13.70B, 28.1%) and Uk Current Year Charge ($1.37B, 2.8%). Together, the two largest regions made up 97.2% of this total.
Compared with fiscal 2024, Europe grew the fastest, rising 15.0% to $13.70B. Uk Current Year Charge fell the most, down 3.5% to $1.37B. Because regions were added or dropped between the two years, part of this reflects how GSK plc regrouped its reporting.
Europe was first reported as a separate region in fiscal 2024. The table also keeps 4 regions that GSK plc no longer reports, so earlier years can still be read on their original basis; use "Show 4 discontinued" beneath the table to see them. This breakdown covers 7 fiscal years between 2015 and 2025, as reported in GSK plc's annual filings.
GSK plc (GSK) breaks its revenue down by revenue line and region. In fiscal 2025, its largest revenue line was Hiv, with $15.37B or 23.5% of the total, followed by Respiratory at $14.14B (21.6%).
Hiv was GSK plc's largest revenue line in fiscal 2025, with $15.37B in revenue, 23.5% of the $65.33B reported across its 10 revenue lines.
Us was GSK plc's largest region in fiscal 2025, with $33.72B in revenue, 69.1% of the $48.78B reported across its 3 regions.
Every figure is taken from GSK plc's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2015 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.